HD-OPM Archive
Topics › Alcohol, smoking & vaping

AHA: up to 1-2 drinks a day shows no risk to possible benefit; heavy drinking is harmful

Louis Nervegna · Nov 06, 2025 · ♥ 8 reactions · 1 comments · original Facebook post
Alcohol, smoking & vapingGuidelines, policy & public health
AI summary & key facts

Louis argues alcohol and CVD claims should rely on evidence, citing decades of prospective studies and the AHA's statement that low intake (no more than 1-2 drinks daily) carries no risk to possible benefit, while 3 or more drinks daily is consistently worse. He notes a randomized red wine trial is underway.

It’s important that we keep the information about alcohol and CVD in the group strictly evidence-based.

We should not allow ideological opinions of influencers or individual clinicians (who are not researchers studying alcohol) to dominate.

It is the hard science that really matters.

This is a question that has been studied extensively for decades by some of the best epidemiologists and scientists in the world. There have been hundreds of prospective studies.

The American Heart Association recently released a scientific consensus statement on this topic, summarizing all of this past research:

↪ AHA statement: low alcohol shows no risk to possible benefit, heavy drinking harms

I am directly quoting the summary section of this recent AHA scientific statement:

“The available evidence suggests no risk to possible risk reduction when alcohol is consumed in low amounts (such as no more than 1 to 2 drinks a day) in regard to coronary artery disease, stroke, sudden death, and possibly heart failure."

It is crucial to emphasize that alcohol consumption is unequivocally DANGEROUS to the heart at high levels. Any possible benefit occurs only at low levels.

The same AHA report also says:

"In stark contrast, heavier alcohol consumption such as binge drinking or consuming on average ≥3 drinks/d is consistently associated with worse outcomes in every cardiovascular disease entity studied."

We have a large randomized trial happening right now in Europe that is directly testing red wine as an intervention to prevent CVD. We should have a definitive answer to the question of whether mild consumption of red wine prevents heart disease in just a few years:

↪ New 5-year RCT from the PREDIMED lead investigator will test red wine versus CVD

Four large randomized trials of the Mediterranean diet have shown that an overall dietary pattern that includes mild consumption of red wine dramatically reduces risk of CVD. These trials have proven that mild red wine consumption is safe (with respect to CVD) in the context of eating a traditional Mediterranean diet:

↪ AHA statement: low alcohol shows no risk to possible benefit, heavy drinking harms

The people who consumed the most red wine in the very large PREDIMED trial (without exceeding moderate levels) had a whopping 50% less risk of having a heart attack or stroke than the people who consumed the least. The researchers tracked wine consumption in this trial with a urinary biomarker that is unique to wine (tartaric acid). This is the most accurate way of tracking alcohol consumption ever used in a long term study to date:

↪ PREDIMED follow-up: urinary tartaric acid links mild-moderate wine to HR 0.5 for CVD

It is true that alcohol consumption increases risk for cancer, particularly breast cancer in women. But this increase in risk is small at mild levels of consumption. The same prospective studies that have demonstrated a small increase in cancer risk from mild alcohol consumption have also demonstrated a very large decrease in CVD risk. You can’t just look at the cancer results of these studies by themselves and ignore the CVD results. It is the whole picture that really matters:

↪ Harvard: 100+ cohorts show 25-40% lower CVD risk with light-to-moderate alcohol

When you look ONLY at studies of wine and exclude other forms of alcohol, there is no detectable increase in rates of cancer at mild levels of consumption:

↪ Meta-analysis of 76 studies finds no link between wine drinking and cancer risk

↪ Meta-analysis of 4.3 million: moderate wine not linked to higher overall cancer risk


#alcoholHD #wineHD #predimedHD #mediterraneanHD

Research cited

The recently published followup of the famous PREDIMED randomized controlled trial is some of the strongest evidence ever published for a possible protective effect of alcohol against CVD. (Emphasis on the word “possible”, because this is not proven and has become a topic of active debate in cardiology.)

The groups were initially randomized to a traditional Mediterranean diet including red wine vs. an AHA style diet without wine. The researchers tracked wine consumption in a subset of both groups with a urinary biomarker that is unique to wine (tartaric acid). This is the most accurate way of tracking alcohol consumption ever used in a long term study to date.

People with urinary levels of tartaric acid reflecting mild-to-moderate wine consumption in the 9 year followup to the trial had significantly lower rates of heart attack, stroke, heart failure, as well as overall cardiovascular mortality.

The hazard ratio for mild-to-moderate wine consumption— as compared to no wine consumption— was 0.5, meaning a 50% relative risk reduction. This is a very large effect, as far as CVD studies go.

The magnitude of this risk reduction is consistent with the 25%-40% risk reduction that has been seen in aggregate in over 100 prospective observational studies:

↪ Harvard: 100+ cohorts show 25-40% lower CVD risk with light-to-moderate alcohol

Quoted:

The implications of this study are far-reaching, particularly in the context of nutritional epidemiology and public health recommendations," wrote Giovanni de Gaetano, MD, PhD, of IRCCS NEUROMED in Pozzilli, Italy, and colleagues in an accompanying editorial.

"The use of an objective biomarker such as urinary tartaric acid represents a significant methodological advancement in alcohol research. It offers a more accurate and reliable measure of wine consumption, which could help resolve some of the ongoing debates about the health effects of alcohol,” they added. "Humans, for various reasons, are often not truthful and tend to either deny or under-report their alcohol intake."

"Moreover, the findings suggest that wine consumption in real-life conditions, unaffected by the often artificial influences of a clinical trial setting, might have a more beneficial impact on cardiovascular health than previously thought," they noted.


Note that we are finally getting a large long-running randomized controlled that directly tests alcohol (red wine) verses cardiovascular disease.

The study will run for 5 years, and also report on secondary endpoints of cancer and all-cause mortality:

↪ New 5-year RCT from the PREDIMED lead investigator will test red wine versus CVD

And it will be run in the same style as the famous PREDIMED trial that tested a Mediterranean diet vs CVD. In fact, it will be run by the same principle investigator as PREDIMED.

It will finally give us the truth on mild-to-moderate alcohol consumption and health, whatever that may be.

#alcoholHD #wineHD #predimedHD #mediterraneanHD

← newer: Mendelian randomization is a poor tool for studying alcohol older: AHA statement: light drinking, no risk to possible benefit; →